Cisplatin News and Research RSS Feed - Cisplatin News and Research

Increasing specific microRNA levels can restore chemotherapy sensitivity in pancreatic cancer cells

Increasing specific microRNA levels can restore chemotherapy sensitivity in pancreatic cancer cells

By increasing the level of a specific microRNA (miRNA) molecule, researchers have for the first time restored chemotherapy sensitivity in vitro to a line of human pancreatic cancer cells that had developed resistance to a common treatment drug. [More]
Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Inside each ovarian tumor, there are good cells and bad cells: The bad cells are fibroblasts. They work to block chemotherapy, which is why nearly every woman with ovarian cancer becomes resistant to treatment. [More]
Action on Hearing Loss funds new study to discover ways of preventing deafness caused by cancer drug

Action on Hearing Loss funds new study to discover ways of preventing deafness caused by cancer drug

A widely used anti-cancer drug, cisplatin, can cause permanent and severe hearing loss, having a devastating impact on the quality of life for cancer survivors. [More]
Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

The chemotherapy drug cisplatin can kill cancer, but it can also cause permanent hearing loss. [More]
Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

From today, women in Scotland with an advanced and incurable form of cervical cancer could benefit from the targeted treatment Avastin, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment. [More]
Fertility 'reassurance' for most chemotherapy-treated female childhood cancer survivors

Fertility 'reassurance' for most chemotherapy-treated female childhood cancer survivors

Both female and male chemotherapy-treated survivors of childhood cancer have an increased risk of impaired fertility, but results suggest that the risk in women is limited to those given specific chemotherapy drugs. [More]
Scientists develop triple-stage 'cluster bomb' system to deliver cisplatin drug through nanoparticles

Scientists develop triple-stage 'cluster bomb' system to deliver cisplatin drug through nanoparticles

Scientists have devised a triple-stage "cluster bomb" system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor. [More]
Women who have survived childhood cancer can become pregnant, shows study

Women who have survived childhood cancer can become pregnant, shows study

For women who have survived childhood cancer, the impact of modern chemotherapy regimens on the likelihood of becoming pregnant is generally small, and most have a good chance of conceiving, according to one of the largest studies of its kind published in The Lancet Oncology. [More]
Conserved gene can act to inhibit lung cancer development, study finds

Conserved gene can act to inhibit lung cancer development, study finds

Scientists believe that "conserved" genes — those found in life forms that range from bacteria to plants, insects and humans — perform vital biological functions across species. And limited research on one of those genes, Nitrilase 1 (Nit1), suggested it acts to inhibit cancer development. [More]
Patients with early-stage NSCLC and low SMARCA4 expression may benefit from platinum-based chemotherapy

Patients with early-stage NSCLC and low SMARCA4 expression may benefit from platinum-based chemotherapy

The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery. [More]
Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute. [More]
Commonly used chemo toxins damage eyesight in childhood cancer survivors

Commonly used chemo toxins damage eyesight in childhood cancer survivors

A study from Lund University in Sweden shows that commonly used chemo toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system. [More]
Combining pain medicine with metal ions could destroy drug-resistant cancer cells

Combining pain medicine with metal ions could destroy drug-resistant cancer cells

Fighting chemoresistant cancer remains a huge challenge that scientists are tackling from as many angles as they can. One alternative approach involves pairing two groups of compounds -- pain medicine and metal ions -- that have individually shown promise as anti-cancer agents. Scientists report in the ACS journal Inorganic Chemistry that combining the two led to new compounds that could destroy drug-resistant cancer cells and leave most normal cells alone in lab tests. [More]
CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

Lung cancer is one of the most prevalent types of cancer, with more than 20,000 new cases diagnosed each year in Spain. Lung adenocarcinomas carrying oncogenic KRAS, the engine driving these tumours in 30% of cases, constitute the most aggressive sub-type because, unlike other types of lung cancer, there are no targeted therapies beyond the standard cisplatin-based treatment. [More]
TSRI scientists reveal workings of key 'relief-valve' in cells

TSRI scientists reveal workings of key 'relief-valve' in cells

A team led by scientists at The Scripps Research Institute has solved a long-standing mystery in cell biology by showing essentially how a key "relief-valve" in cells does its job. [More]

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet. [More]
Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

St. Jude Children's Research Hospital scientists have discovered how an aggressive tumor of the muscle and soft tissue hijacks an export pathway in cells to lay the groundwork for cancer progression and resistance to chemotherapy. [More]
New study improves understanding of metal-based chemotherapy drugs

New study improves understanding of metal-based chemotherapy drugs

What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)? How can we improve their effect and reduce their toxicity? A new study combining experiments and theory has broadened our knowledge of the molecular mechanisms of these active drugs to help experimentalists devising increasingly effective drugs with fewer side effects. [More]
Advertisement
Advertisement